Series Vol. 6 , 03 August 2023
* Author to whom correspondence should be addressed.
Class-1 Major Histocompatibility Complex (MHC) molecules plays an important role in the immune system by exposing antigens to T cells for identification and destruction. Cancer cells often evade the immune system by downregulating MHC expression, avoiding detection from immune cells. Therefore, Class-1 MHC molecules are potential targets for cancer treatments. Recent studies have shown that increasing MHC expression in cancer cells can enhance T cell recognition and enhance the efficacy of immunotherapies, such as checkpoint inhibitors and adoptive cell transfer therapies. In addition, some therapeutic approaches are aimed at directly targeting Class-1 MHC molecules. This paper summarizes the mechanism of MHC expression, the current status of cancer treatments, relevant research status of class-1 MHC as a target in cancer therapy, and how this technique can be improved. These findings highlight the potential of Class-1 MHC as a promising target for cancer treatment, and further research is needed to fully exploit this target for the benefit of cancer patients.
Class-1 MHC, immunotherapy, cancer
1. Ying guo Health 2022 Talking about the treatment of cancer | Cancer | Talking | Methods | Cancer cells | Treatment | Anticancer | Drugs <https://www.cn-healthcare.com/articlewm/20201209/content-1170626>.
2. Chemotherapy Side Effects | American Cancer Society <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html>
3. Radiotherapy | Cancer Treatment | Cancer Research UK <https://www.cancerresearchuk.org/about-cancer/treatment/radiotherapy>
4. Targeted Therapy for Cancer - NCI <https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies>
5. Fei D, Nianwei Q. A Brief Introduction to the Nobel Prizes Related to Immunology[J].Journal of Cellular and Molecular Immunology,2008,No.134(07):746-749.
6. Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 110(2):163-9(2003).
7. Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front Immunol.17;8:292(2017).
8. Lanier LL, Phillips JH. NK cell recognition of major histocompatibility complex class I molecules. Semin Immunol.7(2):75-82(1995).
9. Dhatchinamoorthy K, Colbert J D, Rock K L. Cancer immune evasion through loss of MHC class I antigen presentation[J]. Frontiers in immunology, 12: 636568(2021).
10. Haworth KB, Leddon JL, Chen CY, Horwitz EM, Mackall CL, Cripe TP. Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer.62(4):571-6(2015).
11. Cornel AM, Mimpen IL, Nierkens S. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers (Basel).2;12(7):1760(2020).
12. Xiao H, Long J, Baobao W, Qinfu W, Haige W, Shaohua D, Qian T,Nan J, Changzhen F,Xing J, Fengshan G.MHC.Molecular and Tumor Immunity and Therapeutic Research Progress [J]. Life Sciences,33(07):833-843(2021).
13. Wang, C., Xiong, C., Hsu, Y., Wang, X., & Chen, L. Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and -independent adoptive immunotherapies. Annals Of Blood, 5 (2020).
14. Lakna. Difference between MHC class 1 and 2: Definition, structure, antigen presentation, similarities and differences. Retrieved February 14(2023)
15. Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Frontiers in immunology, 12, 636568 (2021).
16. Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nature Reviews Immunology, 11(12), 823+ (2011).
17. Doordujin, E. M., Lora, A. M., Hall, T. V., Garrido, F., & Aptsiauri, N. The urgent need to recover MHC class I in cancers for effective immunotherapy.15 February 2023, < https://www.sciencedirect.com/science/article/pii/S0952791515001739>
18. Garrido, C., Paco, L., Romero, I., Berruguilla, E., Stefansky, J., Collado, A., Garcia-Lora, A. M. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells(2012).
19. Shklovskaya, E., & Rizos, H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. International Journal of Molecular Sciences, 22(13), 6741(2021).
20. Tau, G., & Rothman, P. Biologic functions of the IFN-gamma receptors. Allergy, 54(12), 1233–1251 (1999).
21. Seidel, J. A., Otsuka, A., & Kabashima, K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in oncology, 8, 86(2018).
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.